The legal action, filed by Levi & Korsinsky, LLP, targets the company’s disclosures between January 13, 2025, and January 29, 2026. According to the filing, Fractyl Health touted the REMAIN-1 Midpoint Cohort results as statistically significant while failing to mention that one of the six study sites lacked a necessary dietary center. This omission allegedly led to higher-than-expected weight regain among patients, undermining the clinical efficacy data presented to shareholders.
In section Releases
Investors File Class Action Against Fractyl Health Over REMAIN-1 Data
A securities class action lawsuit accuses Fractyl Health of misleading investors by omitting critical operational failures at a clinical trial site. The complaint alleges that the company’s SEC filings concealed site-level deficiencies in the REMAIN-1 study, contributing to a 75% share price collapse in early 2026.
Plaintiffs argue that these oversights violated Regulation S-K requirements, specifically Item 105 and Item 303, which mandate the disclosure of material risks and trends. The company’s stock price plummeted from $1.83 on January 28, 2026, to $0.46 just two days later, following the revelation of the six-month results and the underlying site issues. Investors who purchased securities during the class period and suffered losses have until October 20, 2026, to seek lead plaintiff status in the Southern District of New York.
Comments (0)
No comments yet. Be the first!